Is it all Trump's fault for wildly swinging the 'tariff club'? Pfizer: Uncertainty has hindered manufacturing and research and development investment.
① Pfizer CEO Albert Bourla stated that the uncertainty surrounding Trump's proposed pharmaceutical tariffs is hindering the company's manufacturing and R&D investments in the USA; ② Bourla emphasized that the company hopes to see "certainty," meaning clear tariffs or additional incentives, to increase investment in the USA.
Earnings Call Summary | Pfizer(PFE.US) Q1 2025 Earnings Conference
Pfizer Targets $7.7B in Operational Efficiency Savings by 2027, Highlights Strategic R&D Shifts
Viking Among Notable Gainers as Pfizer Raises Deal Prospects
Novartis AG (NVS) Q1 2025 Earnings Call Transcript Summary
Pfizer Shares Are Trading Higher Following a Q1 EPS Beat. The Company Reaffirmed Guidance but Said It Is Trending Towards the Upper End of Its 2025 Adjusted Diluted EPS Guidance Range.